Every 10-Q that Bionano Genomics, Inc. (BNGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BNGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNGO filings page.
Bionano Genomics, Inc. reported higher revenue but continuing losses for the quarter and six months ended June 30, 2026. Total revenue grew to $8.2M for the quarter (up from $6.7M) and $14.9M for the six months (up from $13.2M), driven mainly by instruments and consumables. Quarterly instrument revenue rose 46% to $2.0M and consumables 31% to $4.3M, supported by an installed base of 397 OGM systems and 9,219 flowcells sold in the quarter.
Gross margin was 53% for the quarter, similar to the prior year period. Operating expenses were essentially flat year over year for the six months, but the company remains unprofitable, with a net loss of $7.4M in the quarter and $15.7M year-to-date, widening versus 2025. Accumulated deficit reached $735.3M.
Liquidity is constrained: as of June 30, 2026, Bionano had $3.7M in cash and cash equivalents, $6.2M in short-term investments and $14.8M of working capital. Management used $10.4M of cash in operating activities in the first half and states there is substantial doubt about the company’s ability to continue as a going concern without additional capital. The company fully redeemed its $10.3M JGB convertible debentures at maturity and raised about $1.3M of equity under a $75M at-the-market program.
Bionano Genomics, Inc. reported Q1 2026 revenue of $6.7M, up 4% year over year, driven by higher instrument, consumable, and service revenue, partly offset by lower software sales. Product revenue was $6.1M and service and other revenue $0.6M.
The company’s net loss widened to $8.3M from $3.1M, with operating cash outflows of $5.7M. As of March 31, 2026, Bionano held $3.4M in cash and cash equivalents, $11.0M in short-term investments, and $10.3M in restricted cash and investments.
Management states there is substantial doubt about the company’s ability to continue as a going concern within 12 months without significant new capital. Bionano has $10.3M of Senior Secured Convertible Debentures outstanding and is relying on additional equity or debt financing to fund operations beyond the near term.
Bionano Genomics reported third‑quarter results showing higher revenue and a sharply narrower loss. Q3 2025 revenue was $7.367 million (vs. $6.073 million a year ago), driven by consumables and software, while net loss was $8.503 million (vs. $44.246 million). Cost of revenue fell significantly year over year, and operating expenses dropped without the prior year’s impairment and restructuring charges.
Liquidity remains tight. As of September 30, 2025, the company had $3.065 million in cash and cash equivalents, $18.516 million in investments, and $10.266 million in restricted short‑term investments. Management states there is “substantial doubt” about the company’s ability to continue as a going concern within 12 months without additional financing.
Convertible debentures outstanding totaled $10.266 million in principal, with monthly holder redemptions permitted and a conversion price of $16.20 per share subject to a beneficial ownership cap. Shares outstanding were 9,730,400 at quarter‑end and 10,176,000 as of November 5, 2025.
Bionano Genomics, Inc. reported interim unaudited results showing recurring losses and cash constraints. As of June 30, 2025 the company held $3.6 million in cash and cash equivalents, $12.9 million in short-term investments, $11.0 million in restricted short-term investments and working capital of $18.5 million. The company had $12.1 million principal outstanding under its senior secured convertible debentures and an accumulated deficit of $703.2 million. The company used $6.3 million of cash in operations during the six months ended June 30, 2025 and management stated there is substantial doubt about its ability to continue as a going concern without raising additional capital. Management expects operating losses and negative cash flows to continue for at least the next year and believes existing resources are sufficient into at least the first quarter of 2026 assuming current plans. Significant financing and conversion activity included a reverse stock split (1-for-60), registered direct offerings in January 2025 (~$10.0 million gross proceeds) and at-the-market sales under an ATM Agreement with H.C. Wainwright in 2025 (multiple tranches totaling millions in gross proceeds). Restructuring actions in 2023 and 2024 reduced headcount and caused related charges and impairments previously recorded.